Peps
What is Degarelix?
Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.
Biological role or research focus
Prostate-cancer hormone therapy and cardiovascular outcomes.
Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
- Class / identity
- GnRH receptor antagonist
- Research focus
- Prostate-cancer hormone therapy and cardiovascular outcomes
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Molecular structure
How Degarelix works
GnRH receptor antagonism suppresses the reproductive-hormone pathway through a different receptor approach from GnRH agonists. A mechanistic difference does not itself prove cardiovascular superiority.
Medicine status & clinical context
NCI identifies degarelix, marketed as Firmagon, as FDA-approved for advanced prostate cancer. The PRONOUNCE study examines cardiovascular outcomes within that treatment setting; it does not establish a general longevity or cardiovascular-prevention indication.
NCI identifies degarelix as a prostate-cancer treatment. The featured trial addresses a narrower cardiovascular-safety comparison in people with established atherosclerotic cardiovascular disease.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2021
PRONOUNCE
Did cardiovascular events differ versus leuprolide?
- Population / model
- 545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900.
- Study design
- Randomized open-label comparison with leuprolide over 12 months; adjudicated cardiovascular endpoints; stopped early.
- Main finding
- Major cardiovascular events occurred in 5.5% versus 4.1%: hazard ratio 1.28 (95% CI 0.59–2.79; P=0.53).
- Limits & context
- Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. ↗
BJU international · 2008 Dec · Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. ↗
European urology · 2023 Jun · Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
Degarelix. ↗
· 2012 · Review
Degarelix. ↗
Drugs · 2009 Oct 1 · Journal Article
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Current medicine information should guide precautions and monitoring. PRONOUNCE does not establish that either approach has no cardiovascular risk.
Source: NCI · Degarelix ↗
Identity, route, and evidence limits
Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Did PRONOUNCE prove better cardiovascular safety?
- What population, comparator, and route were actually studied?
- Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did PRONOUNCE prove better cardiovascular safety?
No. The trial stopped early and the event comparison was not statistically significant; the comparative question remained unresolved.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.